Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease
The 2016 Chinese guidelines for the management of dyslipidemia recommended mixed rules that centered around a 10% 10-year risk threshold to initiate statins for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). The present study aimed to evaluate the cost-effectiveness of the guideline statin-initiation strategy and alternative strategies.
A decision analytic model using discrete event simulation with event probabilities based on a validated ASCVD risk prediction tool for Chinese was constructed. Risk factor inputs were from the dataset of a nationally representative survey of middle-aged and elderly Chinese. Data of statin treatment effectiveness were from a published meta-analysis. Other key input data were identified from the literature or relevant databases. The strategies we evaluated were the guideline strategy, a 15% 10-year risk threshold strategy and a 20% 10-year risk threshold strategy. After excluding any extended dominance strategies, the incremental costs per quality-adjusted life year (QALY) gained of each strategy was calculated.
The 20% 10-year risk threshold strategy was an extended dominance option. The incremental costs per QALY gained from the 15% 10-year risk threshold strategy compared with no treatment and the guideline strategy compared with the 15% 10-year risk threshold strategy were CN¥69,309 and CN¥154,944, respectively. The results were robust in most sensitivity analyses.
The guideline strategy and the 15% 10-year risk threshold strategy are optimal when using the three times and the two times the gross domestic product per capita willingness-to-pay standards, respectively.
The authors thank Erli Zhang, MD, Guangyao Li, PhD, and Xiayu Jiao, MS, for their work on reviewing the model. This analysis uses data and information from the CHARLS dataset and codebook. For more information, please refer to charls.pku.edu.cn. The contents of this article are solely the responsibility of the authors.
Concept and overall approach: YJ and WN; data collection: YJ and WN; programming: YJ; analysis and interpretation: YJ and WN; drafting the manuscript: YJ; reviewing and revising the manuscript: YJ and WN.
Compliance with Ethical Standards
The authors did not receive any grant from funding agencies in the public, commercial, or not-for-profit sectors for the submitted work.
Conflict of interest
YJ was a research assistant at the University of Southern California when the submitted work was conducted and is an employee of Amgen Inc. WN was a research fellow at the University of Southern California when the submitted work was conducted and is an employee of Medtronic Inc.
Data Availability Statement
All data generated or analyzed during this study are included in this manuscript (and its online supplemental files). The Excel simulation model used for the analysis and the program code in the model were provided for peer review.
- 1.National Center for Cardiovascular Diseases, Chinese Society of Cardiology, Chinese Diabetes Society, Chinese Society of Endocrinology, Chinese Society of Laboratory Medicine. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1–29. https://doi.org/10.11909/j.issn.1671-5411.2018.01.011.Google Scholar
- 2.Collaboration PS. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet. 2007;370(9602):1829–39.Google Scholar
- 4.Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Part B):2889–934.PubMedGoogle Scholar
- 6.Rabar S, Harker M, O’Flynn N, Wierzbicki AS. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ (Online). 2014;349:g4356.Google Scholar
- 8.Mortensen MB, Falk E. Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention. Eur Heart J. 2016;38(29):2259–63.Google Scholar
- 9.Scottish Intercollegiate Guideline Network. Risk estimation and the prevention of cardiovascular disease. Edinburgh: SIGN; 2007.Google Scholar
- 11.Wei-Wei C, Run-Lin G, Li-Sheng L, Man-Lu Z, Wen W, Yong-Jun W, et al. China cardiovascular diseases report 2015: a summary. J Geriatr Cardiol. 2017;14(1):1.Google Scholar
- 15.The World Bank. Life expectancy at birth, total (years) China; 2017. https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=CN. Accessed 18 Dec 2018.
- 16.Wulf MD. Population pyramids of the World from 1950 to 2100—China 2018; 2018. https://www.populationpyramid.net/china/2018/. Accessed 18 Dec 2018.
- 27.Mullins CD, Rattinger GB, Kuznik A, Koren MJ. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clin Ther. 2008;30:2204–16.PubMedGoogle Scholar
- 30.Yaozh. Information of Drug Winning Bid; 2018. https://data.yaozh.com/yaopinzhongbiao. Accessed 17 May 2018.
- 31.National Bureau of Statistics of China. Consumer price indices, healthcare; 2015. http://data.stats.gov.cn/english/adv.htm?m=advquery&cn=A01. Accessed 17 Oct 2015.
- 34.World Health Organization. Global burden of disease 2004 update: disability weights for diseases and conditions. Geneva: World Health Organization; 2004. http://www.who.int/healthinfo/global_burden_disease/GBD2004_DisabilityWeights.pdf. Accessed 13 Oct 2015.
- 35.Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016.Google Scholar
- 36.Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness in health care. Handbooks in health economic evaluation. New York: Oxford University Press; 2011.Google Scholar
- 38.National Bureau of Statistics of China. Statistical communiqué of the People’s Republic of China on the 2017 National Economic and Social Development; 2018.Google Scholar
- 41.Téllez NEG, Calderón JAM, Muñoz-Galindo IM, Rojas JAD, Roa HOA. Cost-effectiveness of a care program for HIV/AIDS patients affiliated with a health insurer in Colombia, comparing three health care providers nationwide. Value Health Reg Issues. 2016;11:1–8.Google Scholar
- 48.Cylus J, Papanicolas I, Smith PC, European Observatory Health Policy Series. Health system efficiency: how to make measurement matter for policy and management. Copenhagen: World Health Organization; 2016.Google Scholar
- 53.Ouellette DR, Moscoso EE, Corrales JP, Peters M. Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin. Ann Intensive Care. 2015;5(1):9.PubMedGoogle Scholar
- 55.Ganda OP. Statin-induced diabetes: incidence, mechanisms, and implications. F1000Research. 2016;5:1499.Google Scholar
- 58.World Health Organization. Life tables by country, China; 2013. http://apps.who.int/gho/data/?theme=main&vid=60340. Accessed 08 Oct 2015.